• PDF / 185,587 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 36 Downloads / 147 Views

DOWNLOAD

REPORT

1173-5503/20/0867-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 28 Nov 2020 No. 867

1

Recommend Documents

Surveying FDA-approved drugs as new potential inhibitors of N-cadherin protein: a virtual screening approach

128 80 3MB

Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling

185 55 168KB

Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease: Coronavirus Disease

125 68 1MB

Tailor-made amino acid-derived pharmaceuticals approved by the FDA in 2019

146 26 3MB

Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interactio

146 29 839KB

Estimating Discounts for Top Spending Drugs in Medicare Part D

166 20 162KB

RETRACTED ARTICLE: Comparison of two FDA-approved interspinous spacers for treatment of lumbar spinal stenosis: Superion

157 9 1MB

Drugs in Clinical Development for Breast Cancer

117 77 195KB

Drugs in Clinical Development for Prostate Cancer

172 96 179KB

A microscopy-based small molecule screen in primary neurons reveals neuroprotective properties of the FDA-approved anti-

114 80 4MB

The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved

141 34 2MB

Decisions by ICER and NICE discordant for some cancer drugs

144 41 167KB